Verastem(VSTM) - 2020 Q4 - Annual Report

Financial Performance - Total revenue for 2020 was $88.5 million, a significant increase from $17.5 million in 2019, primarily driven by the sale of the COPIKTRA license and related assets[358]. - Product revenue, net for 2020 was $15.2 million, compared to $12.3 million in 2019, reflecting growth in sales[358]. - The company reported a net loss of $67.7 million for 2020, an improvement from a net loss of $149.2 million in 2019[365]. - Total operating expenses decreased to $137.9 million in 2020 from $149.8 million in 2019, reflecting cost-saving measures and reduced headcount[430]. - Selling, general and administrative expenses decreased significantly to $62.8 million in 2020 from $101.2 million in 2019, driven by reduced personnel costs and consulting fees[440]. - Cash used in operating activities decreased to $33.5 million in 2020 from $138.5 million in 2019, primarily due to a decrease in net loss and improved working capital[454]. Research and Development - Research and development expenses for 2020 were $41.4 million, slightly decreased from $45.8 million in 2019, indicating a focus on cost management[358]. - Total research and development expenses for 2020 were $41.376 million, a decrease of 9.8% from $45.778 million in 2019[379]. - COPIKTRA expenses were $13.454 million in 2020, down 47.4% from $25.518 million in 2019[379]. - Defactinib/VS-6766 expenses increased significantly to $12.073 million in 2020 from $1.823 million in 2019[379]. - The company anticipates that research and development expenses may increase significantly in future periods due to costlier development activities[379]. - The company expects to incur significant expenses and operating losses in the foreseeable future due to continued research and development efforts[366]. Cash and Investments - As of December 31, 2020, the company had cash, cash equivalents, and investments totaling $147.2 million, sufficient to fund operations for the next 12 months[365]. - As of December 31, 2020, the company had $147.5 million in cash, cash equivalents, restricted cash, and investments[452]. - The company anticipates that its existing cash resources will be sufficient to fund its obligations for at least the next twelve months[475]. - As of December 31, 2020, the company had cash, cash equivalents, restricted cash, and investments totaling $147.5 million, up from $111.3 million as of December 31, 2019[487]. Licensing and Revenue Recognition - The company recognizes revenue when control of the product is obtained, with COPIKTRA sales recorded at wholesale acquisition costs[392][393]. - Variable consideration for COPIKTRA sales includes trade discounts, chargebacks, and government rebates, impacting net revenue[394][398]. - The company engages in collaboration and licensing arrangements for research and development, which include upfront payments and milestone payments[404]. - The company recognizes revenue from non-refundable upfront fees for licenses when the license is transferred to the customer and they can benefit from it[406]. - Milestone payments are included in the transaction price only if it is probable that significant revenue reversal will not occur, with adjustments made at each reporting period[409]. - The company has not yet recognized any royalty revenue from licensing arrangements, which include sales-based royalties[410]. Debt and Obligations - The company has a total of $28.3 million in aggregate principal amount outstanding for the 2018 and 2020 Notes as of December 31, 2020[474]. - The company has contractual obligations totaling $4.7 million, including operating lease obligations and the 2020 Notes[478]. - The company issued $150.0 million in 5.00% Convertible Senior Notes due 2048, with net proceeds of approximately $145.3 million[463]. - The initial conversion price for the 2020 Notes is approximately $3.25 per share, representing a 153.9% premium to the stock price of $1.28 on November 5, 2020[469]. Market Risk and Exposure - The company’s primary exposure to market risk is interest rate sensitivity, with an immediate 100 basis point change in interest rates expected to have no material effect on the fair market value of its investment portfolio due to its short-term duration and low risk profile[487]. - The company contracts with CROs and contract manufacturers globally, which may expose it to fluctuations in foreign currency rates; however, as of December 31, 2020, an immaterial amount of total liabilities was denominated in currencies other than the functional currency[488]. - The 2018 Notes and 2020 Notes bear interest at a fixed rate, resulting in minimal exposure to changes in interest rates, although future credit rating improvements could lead to higher relative interest rates[489].